Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Haasis, Manuel Alexander ^a   Ceria, Joyce Anne ^a   Kulpeng, Wantanee ^b   Teerawattananon, Yot ^b   Alejandria, Marissa ^c  

^a DEPARTMENT OF HEALTH   (Philippines)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS CONJUGATE VACCINE 10; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HERD IMMUNITY; HUMAN; PHILIPPINES; PNEUMOCOCCAL INFECTION; PREVENTIVE HEALTH SERVICE; PROGRAM SUSTAINABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; ADOLESCENT; ADULT; AGED; CHILD; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; FEMALE; FINANCIAL MANAGEMENT; IMMUNOLOGY; INCOME; INFANT; MALE; MARKOV CHAIN; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PNEUMONIA, PNEUMOCOCCAL; PRESCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; FINANCING, GOVERNMENT; HUMANS; IMMUNIZATION PROGRAMS; INCOME; INFANT; INFANT, NEWBORN; MALE; MARKOV CHAINS; MIDDLE AGED; PHILIPPINES; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84940100057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131156     Document Type: Article

References (57)

1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. The Pediatric infectious disease journal. 2000; 19(3):187-95. PMID: 10749457
2. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. The Pediatric infectious disease journal. 2002; 21(9):810-5. PMID: 12352800
3. Eskola J, Kilpi T, Palmu A, Jokinen J, Eerola M, Haapakoski J, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. New England Journal of Medicine. 2001; 344(6):403-9. PMID: 11172176
4. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine. 2003; 348(18):1737-46. PMID: 12724479
5. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. The Lancet infectious diseases. 2011; 11(10):760-8. doi: 10.1016/S1473-3099(11)70090-1 PMID: 21621466
6. Philippine Statistics Authority National Statistics Office. Population by Age Group, by Sex and by Region: 2010. 2010.
7. Castañeda-Orjuela C, Alvis-Guzmán N, Velandia-González M, De la Hoz-Restrepo F. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine. 2012; 30(11):1936-43. doi: 10.1016/j.vaccine.2012.01.031 PMID: 22266291
8. Chuck AW, Jacobs P, Tyrrell G, Kellner JD. Pharmacoeconomic evaluation of 10-and 13-valent pneumococcal conjugate vaccines. Vaccine. 2010; 28(33):5485-90. doi: 10.1016/j.vaccine.2010.05.058 PMID: 20554066
9. Urueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, et al. Cost-effectiveness analysis of the 10-and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine. 2011; 29(31):4963-72. doi: 10.1016/j.vaccine.2011.04.111 PMID: 21621575
10. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340.
11. Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine. 2011; 29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091 PMID: 21745516
12. Jansen AG, Hak E, Veenhoven RH, Damoiseaux RA, Schilder AG, Sanders EA. Pneumococcal conjugate vaccines for preventing otitis media. The Cochrane database of systematic reviews. 2009;(2:):Cd001480. Epub 2009/04/17. doi: 10.1002/14651858.CD001480.pub3 PMID: 19370566.
13. Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, et al. Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial. PLoS medicine. 2014; 11(6):e1001657. doi: 10.1371/journal.pmed.1001657 PMID: 24892763
14. Kulpeng W, Leelahavarong P, Rattanavipapong W, Sornsrivichai V, Baggett HC, Meeyai A, et al. Cost-utility analysis of 10-and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Vaccine. 2013; 31(26):2839-47. doi: 10.1016/j.vaccine.2013.03.047 PMID: 23588084
15. Department of Health Philippines. Vaccine coverage database, Family Health Office (FHO) Expanded Program on Immunization (EPI). 2014.
16. Capeding MR, Bravo L, Santos J, Kilgore PE, Kim SA, Balter I, et al. Prospective Surveillance Study of Invasive Pneumococcal Disease Among Urban Children in the Philippines. The Pediatric infectious disease journal. 2013; 32(10):e383-e9. doi: 10.1097/INF.0b013e318298dfd5 PMID: 23629024
17. th Asian Congress of Pediatric Infectious Disease: Sep; 2010.
18. Rhodes J, Hyder JA, Peruski LF, Fisher C, Jorakate P, Kaewpan A, et al. Antibiotic use in Thailand: quantifying impact on blood culture yield and estimates of pneumococcal bacteremia incidence. The American journal of tropical medicine and hygiene. 2010; 83(2):301-6. doi: 10.4269/ajtmh.2010.09-0584 PMID: 20682872
19. Central Office for Health Information. Data Structure of Inpatient 2006-2010. Bangkok, Thailand. 2011.
20. Caro RM, Llanes EGDV, Ricalde RC. Prevalence of clinically diagnosed acute otitis media (AOM) in the Philippines: a national survey. WSPID; Melbourne, Australia: Otorhinolaryngology, University of the Philippines College of Medicine-Philippine General Hospital, Manila, Philippines; 2011.
21. Netsawang S, Punpanich W, Treeratweeraphong V, Chotpitayasunondh T. Invasive pneumococcal infection in urban Thai children: a 10-year review. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2010; 93 Suppl 5:S6-12. Epub 2011/02/08. PMID: 21298830.
22. Hsieh YC, Hsueh PR, Lu CY, Lee PI, Lee CY, Huang LM. Clinical manifestations and molecular epidemiology of necrotizing pneumonia and empyema caused by Streptococcus pneumoniae in children in Taiwan. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2004; 38(6):830-5. Epub 2004/03/05. doi: 10.1086/381974 PMID: 14999627.
23. Tan CC, Ong-Mateo M. Management of community-acquired pneumonia in a university hospital: Adherence to recommended practice guidelines. Santo Tomas Journal of Medicine. 2006; 53(2):37-44.
24. World Health Organization. WHO Global Burden of Disease estimates from 1980-2005 for the Western Pacific Region. In: Expanded Program on Immunization, editor. 2009.
25. Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Cost-effectiveness of vnheptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. The European journal of health economics: HEPAC: health economics in prevention and care. 2008; 9(1):7-15. Epub 2007/03/03. doi: 10.1007/s10198-006-0013-6 PMID: 17333089.
26. Monasta L, Ronfani L, Marchetti F, Montico M, Brumatti LV, Bavcar A, et al. Burden of disease caused by otitis media: systematic review and global estimates. PLoS One. 2012; 7(4):e36226. doi: 10.1371/journal.pone.0036226 PMID: 22558393
27. Capeding MR. Laboratory-based surveillance of Streptococcus pneumoniae in tertiary health care centers in the Philippines, preliminary report. Research Institute for Tropical Medicine (RITM), 2012.
28. Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010; 28(25):4192-203. doi: 10.1016/j.vaccine.2010.04.008 PMID: 20417262
29. Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clinical and vaccine immunology. 2010; 17(6):1017-26. doi: 10.1128/CVI.00062-10 PMID: 20427630
30. Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near-Elimination of Otitis Media Caused by 13-Valent Pneumococcal Conjugate Vaccine (PCV) Serotypes in Southern Israel Shortly After Sequential Introduction of 7-Valent/13-Valent PCV. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014; 59(12):1724-32. Epub 2014/08/28. doi: 10.1093/cid/ciu683 PMID: 25159581.
31. Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014; 32(27):3452-9. Epub 2014/04/03. doi: 10.1016/j.vaccine.2014.03.065 PMID: 24690148.
32. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. The Pediatric infectious disease journal. 2013; 32(3):203-7. Epub 2013/04/06. doi: 10.1097/INF.0b013e318275614b PMID: 23558320.
33. Moore MR. Update on Effectiveness and Impact of PCV13 use among U.S. Children. US Center for Disease Control 2014.
34. Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. The Lancet. 2013; 381(9862):214-22.
35. Food and Drug Administration Philippines Center for Drug Registration and Research. Pneumococcal Polysaccharides and Non-Typeable Haemophilus Influenzae (NTHI) protein D conjugate.Vaccine, adsorbed (Synflorix) 0.5 mL Suspension for Injection BR-685, BR-800 & BR-861 [GDS12/IPI13]. 2014.
36. Assessment Report for Synflorix [Internet]. 2009. Available: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/000973/WC500054349.pdf.
37. Rückinger S, Dagan R, Albers L, Schönberger K, von Kries R. Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis. Vaccine. 2011; 29(52):9600-6. doi: 10.1016/j.vaccine.2011.09.011 PMID: 21933696
38. Dagan R. The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media. Current opinion in otolaryngology & head and neck surgery. 2004; 12(6):488-94.
39. Musher DM. Pneumococcal vaccine-direct and indirect ("herd") effects. New England Journal of Medicine. 2006; 354(14):1522. PMID: 16598050
40. Salo H, Sintonen H, Pekka Nuorti J, Linna M, Nohynek H, Verho J, et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scandinavian journal of infectious diseases. 2005; 37(11-12):821-32. PMID: 16308215
41. Butler JR, McIntyre P, Raina MacIntyre C, Gilmour R, Howarth AL, Sander B. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine. 2004; 22(9):1138-49.
42. Bin-Chia Wu D, Chang C-J, Huang Y-C, Wen Y-W, Wu C-L, Fann CS-J. Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach. Value in Health. 2012; 15(1):S15-S9. doi: 10.1016/j.jval.2011.11.013 PMID: 22265061
43. Average exchange rate Philippine Peso per US Dollar December 2013 [Internet]. [cited 04/12/2013]. Available: http://www.x-rates.com/average/?from=USD&to=PHP&amount=1.00&year=2013.
44. MIMS Philippines. Prevenar 13 and Synflorix 2013 [cited 2013 December 6]. Available: http://www.mims.com/Philippines.
45. Immunization standards, WHO prequalified vaccines, February 2014 [Internet]. [cited 21/02/2014]. Available: http://www.who.int/immunization-standards/vaccine-quality/PQ-199-Pneumococcal-GSK-2dose/en/.
46. EPPI-Centre Cost Converter [Internet]. 2014 [cited 01/03/2014]. Available: http://eppi.ioe.ac.uk/costconversion/Default.aspx.
47. Kulpeng W, Sornsrivichai V, Chongsuvivatwong V, Rattanavipapong W, Leelahavarong P, Cairns J, et al. Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections. BMC pediatrics. 2013; 13(1):1-9.
48. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13- valent pneumococcal conjugate vaccine. Vaccine. 2011; 29(49):9127-31. doi: 10.1016/j.vaccine.2011.09.112 PMID: 21983361
49. National Center for Pharmaceutical Access and Management Department of Health Philippines. Minutes of the Fourth Meeting of the Formulary Executive Council on 07 June 2013.
50. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. The Lancet. 2011; 378(9807):1962-73.
51. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. The Pediatric infectious disease journal. 2007; 26(6):468-72. PMID: 17529860
52. Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, Purdy J. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine. 2013; 31(42):4881-7. Epub 2013/08/10. doi: 10.1016/j.vaccine.2013.07.054 PMID: 23928466.
53. Gonzalez Martinez F, Navarro Gomez ML, Saavedra Lozano J, Santos Sebastian MM, Rodriguez Fernandez R, Gonzalez Sanchez M, et al. [Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of the 7-valent conjugate vaccine]. Anales de pediatria (Barcelona, Spain: 2003). 2014; 80(3):173-80. Epub 2013/06/26. doi: 10.1016/j.anpedi.2013.05.003 PMID: 23796611.
54. Falup-Pecurariu O. Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines. Biomedical journal. 2012; 35(6):450-6. Epub 2013/02/28. doi: 10.4103/2319-4170.104409 PMID: 23442357.
55. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of sevenvalent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. The Lancet. 2006; 368(9546):1495-502.
56. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène J-P, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. The Pediatric infectious disease journal. 2009; 28(4): S66-S76. doi: 10.1097/INF.0b013e318199f8ef PMID: 19325449
57. Van Hoek AJ, Andrews N, Waight PA, George R, Miller E. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PloS one. 2012; 7(7):e39150. doi: 10.1371/journal.pone.0039150 PMID: 22815698